Elekta Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Decisions with the Full Value Chain Report
This Elekta Value Chain Analysis gives you a clear view of how Elekta creates value through its support activities and primary activities in one practical framework. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Elekta's firm infrastructure is built around strict regulatory compliance, quality systems, and global program control, which matters in a medical device business where approvals and risk control shape hospital trust.
Its FY2025 annual reporting still centers on a large installed base and recurring service work, so governance, audit trails, and lifecycle oversight stay critical for cancer centers that rely on uptime and safe use.
This back-office strength supports faster product approvals, tighter clinical risk management, and steadier long-term revenue from service and upgrades.
Human Resource Management
Elekta's human resource management depends on engineers, clinical specialists, software developers, and field service teams with deep radiotherapy know-how. In FY2024/25, this talent base supported high-value systems where a single installation or service error can hurt revenue and trust.
Hiring and keeping these specialists matters because Elekta sells complex treatment platforms, not simple devices. Skilled teams help protect product quality, speed up installations, and support the after-sales service that hospitals rely on every day.
That makes people a core part of Elekta's value chain, not just a back-office cost. Strong retention also helps preserve clinical expertise, which is critical when customers are making long-cycle capital spending decisions.
Technology Development
Elekta's technology development focuses on radiation therapy systems, radiosurgery, brachytherapy, and oncology workflow software. In fiscal 2025, this R&D drive supported finer dose control, better imaging, and more automation, which helps clinicians tailor treatment to each patient. It also refreshes Elekta's installed base with upgrades that improve planning speed and treatment accuracy.
Procurement
Elekta must source precision electronics, imaging parts, mechanical subassemblies, and software tools from qualified suppliers to support regulated cancer-care systems. In FY2025, Elekta reported net sales of SEK 18.1 billion, so procurement scale is material to cost and supply control. Tight supplier screening also helps protect quality and lead times for complex capital equipment.
Elekta's FY2025 support engine: compliance, talent, R&D, and sourcing
Elekta's support activities in FY2025 stayed anchored in compliance, talent, R&D, and sourcing, which is vital in a regulated cancer-care business with SEK 18.1 billion in net sales.
Its infrastructure and quality systems protect approvals, audits, and uptime across a large installed base, while skilled engineers and field teams keep complex radiotherapy systems running safely.
R&D for treatment platforms and oncology software supports upgrades, better imaging, and tighter dose control, and procurement of precision parts helps manage cost, lead times, and product quality.
| FY2025 support pillar | Key point |
|---|---|
| Infrastructure | Compliance and quality control |
| HR | Engineers and service specialists |
| Technology | Radiotherapy and workflow R&D |
| Procurement | Precision parts and supplier control |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
In FY2025, Elekta reported net sales of about SEK 17 billion, so inbound logistics stayed central to keeping its treatment-system build schedule on track. Elekta receives high-spec parts and subassemblies that need tight traceability and zero-slip quality checks, because one bad lot can stop assembly on regulated systems. Strong supplier control matters here: even a short delay can hit delivery timing, cash flow, and customer installs.
Operations
In FY2024/25, Elekta reported net sales of SEK 17.3 billion, and its operations turn that scale into finished radiation therapy and software systems. The work covers assembly, integration, test, and validation so each machine can deliver precise dose planning and treatment delivery.
This step matters because Elekta serves customers in more than 120 countries, so reliability has to be built in before shipment. Strong operations help convert complex parts into clinically usable platforms with lower error risk and faster hospital deployment.
Outbound Logistics
Elekta's outbound logistics moves large radiation-therapy systems to hospitals and cancer centers, with timed delivery, site-readiness checks, and install windows that can decide when revenue starts. In FY2024/25, Elekta served customers in about 120 countries, so late shipping or a missed crane slot can slow commissioning and push cash collection back. Reliable dispatch also helps protect adoption, because these systems are often bought as multi-year, high-value capital deals.
Marketing and Sales
Elekta's marketing and sales are built around specialist account teams that sell into hospitals and public tenders, so proof matters more than pitch. The sales cycle is long because buyers weigh clinical outcomes, workflow fit, service uptime, and total cost of ownership, not just device price. That makes clinical evidence and reference sites central to closing deals, especially in oncology where procurement is multi-stakeholder and budget-led.
In FY2025, this model kept Elekta tied to high-value, relationship-based contracts rather than fast repeat sales, so pipeline quality and tender wins drive revenue more than volume.
Service
Elekta's service activity covers installation support, training, maintenance, remote diagnostics, and software upgrades, so hospitals can keep radiotherapy systems running with less downtime. This protects the installed base and keeps clinical workflows stable, which matters because each outage can disrupt patient scheduling and care delivery.
It also adds recurring post-sale revenue after the initial equipment sale, since maintenance contracts and software updates often continue for years. In Elekta's 2025 fiscal year, this service layer remains a key part of the value chain because it helps defend customer relationships and extend the life of each system.
Elekta FY2025: Global radiotherapy operations, delivery, and service
Elekta's primary activities in FY2024/25 turned SEK 17.3 billion of net sales into regulated radiotherapy systems, with assembly, test, and validation doing most of the heavy lift. Its outbound delivery to customers in about 120 countries makes timing and site readiness critical. Service then protects uptime through install support, training, maintenance, and remote diagnostics.
| Primary activity | FY2025 fact |
|---|---|
| Operations | SEK 17.3 billion net sales |
| Market reach | About 120 countries |
| Service | Maintenance and remote diagnostics |
Preview Before You Purchase
Elekta Reference Sources
This is the actual Elekta Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see is what you get. Once purchased, the complete version is unlocked immediately.
Frequently Asked Questions
Elekta's value chain emphasizes 3 core product lines, 2 clinical end markets, and 5 tightly linked activity blocks. The chain turns regulated hardware, software, and service into precise cancer and brain treatment solutions. The biggest value capture comes after installation, when the installed base generates maintenance, upgrades, and workflow software demand.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.